Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Current positioning and future development of belantamab mafodotin and other antibody-drug conjugates to treat multiple myeloma.

Frontiers in oncology·2026
Same author

Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients.

Blood cancer journal·2026
Same author

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).

American journal of hematology·2026
Same author

MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma.

Cells·2026
Same author

Bedaquiline amplifies proteasome inhibitor efficacy and overcomes resistance in multiple myeloma.

Haematologica·2026
Same author

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.

Nature medicine·2026

相关实验视频

Updated: Sep 19, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K

多发性骨髓瘤打开包装

Francesca Gay1, Edoardo Marchetti1, Giuseppe Bertuglia1

  • 1Division of Hematology, AOU Città della Salute e della Scienza, Department of Molecular Biotechnology and Health Science, University of Torino, Torino, Italy.

Hematological oncology
|June 15, 2025
PubMed
概括

多发性骨髓瘤 (MM) 是一种血细胞癌. 目前的治疗改善了生存率,但对于复发/耐药病例需要新的治疗方法,包括CAR T细胞治疗和新药.

科学领域:

  • 血液瘤学 血液瘤学
  • 癌症生物学 癌症生物学

背景情况:

  • 多发性骨髓瘤 (MM) 是一种由克隆性血细胞驱动的骨髓恶性瘤.
  • 目前的治疗方法,包括蛋白酶体抑制剂和干细胞移植,改善了生存率.
  • 复发性和耐火性MM仍然存在重大临床挑战.

研究的目的:

  • 审查多发性骨髓瘤的诊断标准,预后因素和反应评估.
  • 为了总结当前多发性骨髓瘤的治疗环境.
  • 为突出多发性骨髓瘤的新兴治疗策略.

主要方法:

  • 对诊断标准和预后特征的文献综述.
  • 对多发性骨髓瘤当前治疗方式的分析.
  • 目前正在进行的临床试验和新型治疗剂的概述.

主要成果:

  • 建立了MM的诊断标准和预后指标.
  • 详细概述标准治疗方法,包括蛋白酶体抑制剂,免疫调节药物和干细胞移植.
  • 确定有前途的新疗法,如CAR T细胞疗法,双特异性抗体和Cereblon E3联酶调节剂药物.

结论:

关键词:
免疫疗法 免疫疗法骨髓瘤多样性 骨髓瘤多样性响应评估 响应评估 响应评估阶段化 阶段化

更多相关视频

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K

相关实验视频

Last Updated: Sep 19, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K
  • 多发性骨髓瘤治疗已取得进展,显著改善了患者的治疗结果.
  • 尽管取得了进展,但在管理复发性和耐药性疾病方面仍然存在挑战.
  • 新兴疗法有望进一步改善MM的治疗和患者的存活率.